Jose Ignacio Juárez Del Río
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jose Ignacio Juárez Del Río has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Adrián Muinelo Paul
Department of Cardiac Surgery, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, Spain
1 shared publication - Adrián Torres Clarés
Department of Cardiac Surgery, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, Spain
1 shared publication Ali Ayaon Albarrán
1 shared publicationAngel Aroca Peinado
1 shared publicationArnaldo Javier Estigarribia Bernal
Department of Cardiac Surgery, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, Spain
1 shared publication- Carlota Recio
Doctoral Unit, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain, Spain
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Preprints.org
Extensive Bilateral Internal Thoracic Artery Grafting in a Population with a High Burden of Diabetes: Sternal Safety, Survival and Stroke in a Weighted Retrospective Cohort Study
Background/Objectives: Concern about sternal wound complications limits bilateral internal thoracic artery (BITA) grafting, particularly in patients with diabetes and obesity. We evaluated the mid-term results of a program of extensive BITA grafting in the Canary Islands, the Spanish region with the highest diabetes-related mortality. Methods: We retrospectively analyzed 667 consecutive patients undergoing non-emergent, first-time, isolated multivessel coronary artery bypass grafting between 2017 and 2025; 472 (70.8%) received BITA and 195 (29.2%) single internal thoracic artery (SITA) grafting. Outcomes were compared using inverse probability of treatment weighting. Results: Half of the patients (49.8%) had diabetes. Median follow-up was 46.2 months. After weighting, BITA and SITA grafting did not differ in all-cause mortality (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.55–1.47; p = 0.68), myocardial infarction (HR 0.65; 95% CI 0.28–1.51), repeat revascularization (HR 0.76; 95% CI 0.32–1.83) or major adverse cardiovascular events (HR 0.81; 95% CI 0.52–1.25). Stroke was less frequent after BITA grafting (HR 0.24; 95% CI 0.07–0.77; p = 0.016). Sternal wound complications occurred in 8.7% vs. 6.2% of patients (odds ratio 1.45; 95% CI 0.75–2.82; p = 0.35), with no excess among patients with diabetes (8.8% vs. 8.7%). Conclusions: In a population with a high burden of diabetes, BITA grafting was delivered to 70.8% of unselected patients without a significant excess of sternal wound complications. It did not improve mid-term survival, but stroke was less frequent after BITA grafting, a hypothesis-generating finding that requires confirmation.
- 13 November 2026
- Published by MDPI AG in Preprints.org
Open AccessExtensive Bilateral Internal Thoracic Artery Grafting in a Population with a High Burden of Diabetes: Sternal Safety, Survival and Stroke in a Weighted Retrospective Cohort Study
Background/Objectives: Concern about sternal wound complications limits bilateral internal thoracic artery (BITA) grafting, particularly in patients with diabetes and obesity. We evaluated the mid-term results of a program of extensive BITA grafting in the Canary Islands, the Spanish region with the highest diabetes-related mortality. Methods: We retrospectively analyzed 667 consecutive patients undergoing non-emergent, first-time, isolated multivessel coronary artery bypass grafting between 2017 and 2025; 472 (70.8%) received BITA and 195 (29.2%) single internal thoracic artery (SITA) grafting. Outcomes were compared using inverse probability of treatment weighting. Results: Half of the patients (49.8%) had diabetes. Median follow-up was 46.2 months. After weighting, BITA and SITA grafting did not differ in all-cause mortality (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.55–1.47; p = 0.68), myocardial infarction (HR 0.65; 95% CI 0.28–1.51), repeat revascularization (HR 0.76; 95% CI 0.32–1.83) or major adverse cardiovascular events (HR 0.81; 95% CI 0.52–1.25). Stroke was less frequent after BITA grafting (HR 0.24; 95% CI 0.07–0.77; p = 0.016). Sternal wound complications occurred in 8.7% vs. 6.2% of patients (odds ratio 1.45; 95% CI 0.75–2.82; p = 0.35), with no excess among patients with diabetes (8.8% vs. 8.7%). Conclusions: In a population with a high burden of diabetes, BITA grafting was delivered to 70.8% of unselected patients without a significant excess of sternal wound complications. It did not improve mid-term survival, but stroke was less frequent after BITA grafting, a hypothesis-generating finding that requires confirmation.
- Open Access
- 1 October 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (10) , 1150
The ligament of Marshall as a therapeutic target in atrial fibrillation: from anatomy to catheter-based and surgical management—a narrative review
Background and Objective: Long regarded as an inconsequential embryological remnant, the ligament of Marshall (LOM) is now recognized as a treatable component of the atrial fibrillation (AF) substrate. This review synthesizes the anatomical, electrophysiological and clinical evidence behind that shift and compares the two routes to the LOM: percutaneous retrograde ethanol infusion into the vein of Marshall (EIVOM) during catheter ablation, and direct division during thoracoscopic surgery. Both act on the same epicardial structure; only the route of access differs. Methods: A structured literature search of PubMed, Embase and Web of Science covered the embryology, anatomy, histology and electrophysiology of the LOM and clinical studies of both routes. Two authors screened and selected records independently. Given the heterogeneity of study designs, findings were synthesized narratively. Key Content and Findings: The LOM is a neuro-muscular remnant of the embryonic left superior vena cava that contributes to AF through three mechanisms: triggers arising from insulated myocardial “Marshall bundles”, autonomic modulation via adjacent ganglionated plexi, and preferential conduction across the mitral isthmus. Five randomized trials of EIVOM-based strategies have enrolled more than 1,100 patients; pooled analysis shows improved 12-month freedom from any atrial arrhythmia (risk ratio 1.16, 95% confidence interval: 1.04–1.29; number needed to treat 10) and less repeat ablation, without excess major complications (2.5% vs. 2.8%) but with more overall complications and longer fluoroscopy. Crucially, no trial has tested ethanol infusion in isolation; the observed benefit reflects composite lesion sets. Thoracoscopic division interrupts the entire ligament independent of venous anatomy but has never been a randomized variable; randomized evidence for thoracoscopic and hybrid strategies overall ranges from neutral (CASA-AF) to positive (CONVERGE, HARTCAP-AF). Guidelines recognize both as options in selected patients without mandating routine LOM division. Conclusions: The LOM is a reproducible, anatomically defined target reachable percutaneously or by surgical division within a comprehensive AF ablation strategy. The supporting evidence is markedly asymmetric: randomized data exist for EIVOM-based strategies but never for ethanol infusion alone, none at all for surgical division, and the two routes have never been compared head-to-head. Its incremental benefit beyond pulmonary vein and posterior wall isolation remains undefined.
- 1 October 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (10) , 1150
Open AccessThe ligament of Marshall as a therapeutic target in atrial fibrillation: from anatomy to catheter-based and surgical management—a narrative review
Background and Objective: Long regarded as an inconsequential embryological remnant, the ligament of Marshall (LOM) is now recognized as a treatable component of the atrial fibrillation (AF) substrate. This review synthesizes the anatomical, electrophysiological and clinical evidence behind that shift and compares the two routes to the LOM: percutaneous retrograde ethanol infusion into the vein of Marshall (EIVOM) during catheter ablation, and direct division during thoracoscopic surgery. Both act on the same epicardial structure; only the route of access differs. Methods: A structured literature search of PubMed, Embase and Web of Science covered the embryology, anatomy, histology and electrophysiology of the LOM and clinical studies of both routes. Two authors screened and selected records independently. Given the heterogeneity of study designs, findings were synthesized narratively. Key Content and Findings: The LOM is a neuro-muscular remnant of the embryonic left superior vena cava that contributes to AF through three mechanisms: triggers arising from insulated myocardial “Marshall bundles”, autonomic modulation via adjacent ganglionated plexi, and preferential conduction across the mitral isthmus. Five randomized trials of EIVOM-based strategies have enrolled more than 1,100 patients; pooled analysis shows improved 12-month freedom from any atrial arrhythmia (risk ratio 1.16, 95% confidence interval: 1.04–1.29; number needed to treat 10) and less repeat ablation, without excess major complications (2.5% vs. 2.8%) but with more overall complications and longer fluoroscopy. Crucially, no trial has tested ethanol infusion in isolation; the observed benefit reflects composite lesion sets. Thoracoscopic division interrupts the entire ligament independent of venous anatomy but has never been a randomized variable; randomized evidence for thoracoscopic and hybrid strategies overall ranges from neutral (CASA-AF) to positive (CONVERGE, HARTCAP-AF). Guidelines recognize both as options in selected patients without mandating routine LOM division. Conclusions: The LOM is a reproducible, anatomically defined target reachable percutaneously or by surgical division within a comprehensive AF ablation strategy. The supporting evidence is markedly asymmetric: randomized data exist for EIVOM-based strategies but never for ethanol infusion alone, none at all for surgical division, and the two routes have never been compared head-to-head. Its incremental benefit beyond pulmonary vein and posterior wall isolation remains undefined.
- Open Access
- 27 September 2023
- Published by Heighten Science Publications Corporation in Journal of Cardiology and Cardiovascular Medicine
- Vol. 8 (3) , 122-129
Conduit quality control protocol in CABG
Cardiac revascularization surgery has a long history. Its results and safety are well known. Nonetheless, the long-term patency rate of certain grafts used in cardiac revascularization is non-optimal, and CABG is associated with a risk of cerebrovascular stroke due to aortic manipulation. We have developed a simple control quality protocol of the anastomosis performed in CABG, aiming to improve the long-term patency of certain grafts used in cardiac revascularization surgery and reduce the risk of cerebrovascular stroke in those patients.
- 27 September 2023
- Published by Heighten Science Publications Corporation in Journal of Cardiology and Cardiovascular Medicine
- Vol. 8 (3) , 122-129
Open AccessConduit quality control protocol in CABG
Cardiac revascularization surgery has a long history. Its results and safety are well known. Nonetheless, the long-term patency rate of certain grafts used in cardiac revascularization is non-optimal, and CABG is associated with a risk of cerebrovascular stroke due to aortic manipulation. We have developed a simple control quality protocol of the anastomosis performed in CABG, aiming to improve the long-term patency of certain grafts used in cardiac revascularization surgery and reduce the risk of cerebrovascular stroke in those patients.